Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) Return on Equity (2016 - 2025)

Traws Pharma (TRAW) has disclosed Return on Equity for 14 consecutive years, with 1.46% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity fell 409.0% to 1.46% in Q3 2025 year-over-year; TTM through Sep 2025 was 1.46%, a 409.0% decrease, with the full-year FY2024 number at 13.59%, up 1463.0% from a year prior.
  • Return on Equity was 1.46% for Q3 2025 at Traws Pharma, up from 1.94% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 10.7% in Q1 2025 to a low of 2.32% in Q1 2024.
  • A 5-year average of 0.51% and a median of 0.61% in 2021 define the central range for Return on Equity.
  • Biggest YoY gain for Return on Equity was 1303bps in 2025; the steepest drop was -471bps in 2025.
  • Traws Pharma's Return on Equity stood at 0.34% in 2021, then plummeted by -85bps to 0.64% in 2022, then tumbled by -153bps to 1.61% in 2023, then skyrocketed by 625bps to 8.46% in 2024, then plummeted by -117bps to 1.46% in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Return on Equity are 1.46% (Q3 2025), 1.94% (Q2 2025), and 10.7% (Q1 2025).